Sonova Shares Slip as Hearing Aid Giant Lowers Growth Outlook and Plans Sennheiser Exit 
Henkel in Advanced Talks to Acquire Olaplex at $2 Per Share 
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
U.S. Stock Futures Steady as Iran Reviews U.S. Ceasefire Proposal 
WTO Reform Talks Begin in Cameroon Amid Global Trade Tensions 
Innate Pharma Reports 55% Revenue Drop and €49.2M Net Loss for 2025 
Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push 
Iran Allows Oil Tankers Through Strait of Hormuz Amid U.S. Negotiations 
Australia's Inflation Eases in February but Core Pressures Persist 
Oil Prices Slip as Middle East Tensions Ease, Heading for Weekly Loss 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
NAB Plans to Cut 170 Jobs While Expanding Offshore Operations 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
Oil Prices Climb as Iran Reviews U.S. Peace Proposal Amid Middle East Tensions 
Gold Prices Surge on U.S.-Iran Ceasefire Reports 
Bank of Japan Unveils New Inflation Gauge to Support Case for Future Rate Hikes 
Daewoong’s Nabota was banned by the U.S. International Trade Commission late last year. The agency imposed a 21-month import and sale ban on the South Korean company’s botulinum toxin product brand.
The prohibition resulted from the verdict handed down by the ITC regarding Medytox’s 5-year legal battle against Daewoong Pharmaceutical. Apparently, the commission ruled in favor of the Gangnam-gu-based biopharmaceutical company. The two Korean firms are battling in court over the misappropriation of trade secrets complaints.
ITC revokes ban on Daewoong’s Nabota
This week, the US ITC has lifted the restriction on Daewoong’s botulinum toxin products. This means the firm can now resume the sale and import of its Nabota products that is also known as Jeuveau, in the U.S.
The Korea Herald reported that the latest decision would let Evolus, Daewoong Pharma’s partner based in the United States, to start selling Nabota in the region again. In any case, the ban was lifted after Medytox, Evolus, and AbbVie, Allergan’s parent company, agreed to resolve their dispute in February.
As part of the deal, the three corporations will also dissolve all the remaining cases at the ITC, including the sale of Nabota in the U.S. and other countries where Evolus has licensing rights.
How the companies settled the dispute
Moreover, it was revealed that Evolus agreed to pay Medytox and Allergan $35 million that will be paid in a series of lump sums in the span of two years. The Daewoong partner has to pay royalties to Medytox and Allergan based on Nabota’s net sales for 21 months. After this, Evolus will be paying royalties to Medytox alone.
Allergan is also involved in the case of Daewoong because botulinum toxin is the main component in Botox, a type of treatment for wrinkles. Allergan is the company that sells Botox.
Meanwhile, as per Pulse News, Daewoong Pharmaceutical Co.’s shares have increased on Tuesday, May 4. The numbers have jumped by 5.93 percent to close at ₩134,000 or around $119.37. This figure is expected to increase now that Nabota is being allowed to be sold again in the United States further.
